Visualisation of a Digital Care Pathway.
Visualisation of a Digital Care Pathway in Limburg, in Context of Digital Care Support as a Stepping Stone for Flanders.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
Good quality of care requires a multidisciplinary approach, especially with chronic illnesses. Therefore, all members of the care team should be adequately informed and communicate well with each other. Additionally, patients should have a key role in their treatment plan. To successfully optimize self care, patients have to be well-informed about pathogenesis, treatments and complications so that expectations are realistic and attainable goals can be set. Currently, access to this relevant data is fragmented and often unavailable.
The newly developed application creates a central platform where all relevant data, educational material, medication scheme... are available for both the patient and healthcare professionals. The targeted study population are patients with type 2 diabetes who will be recruited by their general practitioner (GP) over a period of 3 months. When patients are interested in partaking, they will be contacted by a healthcare professional who will function as a Single Point of Contact (SPOC) for the patient during the entirety of the study with a maximum duration of 6 months. The SPOC helps with the start up of the application, collects administrative data and contacts the participants at regular intervals to help with difficulties in using the application. Furthermore, the SPOC will administer a questionnaire determining patient involvement and experience at the start and end of the study, as well as conduct an in-depth interview when the study is completed. Throughout the study, other questionnaires will be digitally available for the patient as part of the care path. These patient reported outcome and experience measures (PROM/PREM) will support healthcare professionals in providing a more integral care.
Consequently, involved healthcare professionals will also be contacted, informed and asked to complete a questionnaire once healthcare professionals agree to participate in the study. This questionnaire will focus on the information and communication needs between members of the care team and will also be repeated at the end, followed by an in-depth interview.
Тип исследования
Регистрация (Ожидаемый)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: Emilie Weyens
- Номер телефона: +32 11 33 51 17
- Электронная почта: emilie.weyens@jessazh.be
Учебное резервное копирование контактов
- Имя: Jolien Nelissen, Dr
- Номер телефона: +32 11 33 51 18
- Электронная почта: jolien.nelissen@jessazh.be
Места учебы
-
-
Limburg
-
Hasselt, Limburg, Бельгия, 3500
- Рекрутинг
- Jessa Hospital
-
Контакт:
- Emilie Weyens
- Электронная почта: emilie.weyens@jessazh.be
-
Контакт:
- Jolien Nelissen, Dr.
- Электронная почта: jolien.nelissen@jessazh.be
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria for cohort 1 and 2:
- patients with type 2 diabetes (voortraject and zorgtraject)
- independent and mentally competent
- digitally literate and in possession of an email address
- mastered the Dutch language
- able to visit the GP (no house calls)
Additional inclusion criteria for cohort 2 :
- presence of a home nurse in the context of the Diabetes care
- presence of a home care service
Exclusion Criteria:
- patients type 2 Diabetes enrolled in the Diabetes convention
- pregnant patients
- illiterate people
- patients living in a residential care center
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Другой
- Распределение: Нерандомизированный
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: patients
Implementation and visualisation of digital care path. Pre measurement: questionnaire quantifying patient involvement and experience on a 5-p Likert scale. Post measurement: questionnaire quantifying patient involvement and experience on a 5-p Likert scale, questionnaire quantifying usability of the tool and in-depth interview. |
The implementation and visualisation of a digital care path, specifically designed for patients with type 2 diabetes and their care team.
The digital care path wil include: 1) a timeline with appointments, messages and questionnaires 2) Diabetes related articles 3) a page for monitoring clinical parameters and goals 4) a section displaying information on their care team and personal health records.
The aim of this intervention is to evaluate whether providing a central platform for all data will increase patient empowerment and involvement.
Secondly it will also evaluate whether the communication between healthcare professionals improves when selected data is readily available for the entire care team.
|
|
Экспериментальный: healthcare professionals
Implementation and visualisation of digital care path. Pre measurement: questionnaire quantifying communication needs and experiences on a 5-p Likert scale. Post measurement: questionnaire quantifying communication needs and experiences on a 5-p Likert scale, questionnaire quantifying usability of the tool and in-depth interview. |
The implementation and visualisation of a digital care path, specifically designed for patients with type 2 diabetes and their care team.
The digital care path wil include: 1) a timeline with appointments, messages and questionnaires 2) Diabetes related articles 3) a page for monitoring clinical parameters and goals 4) a section displaying information on their care team and personal health records.
The aim of this intervention is to evaluate whether providing a central platform for all data will increase patient empowerment and involvement.
Secondly it will also evaluate whether the communication between healthcare professionals improves when selected data is readily available for the entire care team.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in patient empowerment and involvement
Временное ограничение: For a minimum of 12 weeks
|
Primary outcome measures will be determined with the aid of a questionnaire scoring answers on a 5p-Likert scale. Due to limited availability of validated questionnaires in Dutch, a custom set of questions was generated. Starting from validated English questionnaires on each topic, the Delphi method was used to reach consensus in selecting the final questions. At the end of the study, an in-depth interview will take place with a predefined topic list. |
For a minimum of 12 weeks
|
|
Change in care team communication and sharing of data
Временное ограничение: For a minimum of 12 weeks
|
Primary outcome measures will be determined with the aid of a questionnaire scoring answers on a 5p-Likert scale. Due to limited availability of validated questionnaires in Dutch, a custom set of questions was generated. Starting from validated English questionnaires on each topic, the Delphi method was used to reach consensus in selecting the final questions. At the end of the study, an in-depth interview will take place with a predefined topic list. |
For a minimum of 12 weeks
|
|
Usability and acceptance of the application in patients and healthcare professionals
Временное ограничение: For a minimum of 12 weeks
|
Primary outcome measures will be determined with the aid of a questionnaire scoring answers on a 5p-Likert scale. Due to limited availability of validated questionnaires in Dutch, a custom set of questions was generated. Starting from validated English questionnaires on each topic, the Delphi method was used to reach consensus in selecting the final questions. At the end of the study, an in-depth interview will take place with a predefined topic list. |
For a minimum of 12 weeks
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
User characteristics of the application.
Временное ограничение: for a minimum of 12 weeks
|
Data will be collected from logs, available in the back office of the application
|
for a minimum of 12 weeks
|
|
Possible change,impact on personal clinical parameters: HbA1c
Временное ограничение: for a minimum of 12 weeks
|
HbA1c will be expressed in %
|
for a minimum of 12 weeks
|
|
Possible change,impact on personal clinical parameters: blood pressure
Временное ограничение: For a minimum of 12 weeks
|
Both systolic and diastolic blood pressure will be measured, expressed in mmHg.
|
For a minimum of 12 weeks
|
|
Possible change,impact on personal clinical parameters: glycemia
Временное ограничение: For a minimum of 12 weeks
|
Glycemia will be expressed in mg/dl.
|
For a minimum of 12 weeks
|
|
Possible change,impact on personal clinical parameters: girth
Временное ограничение: For a minimum of 12 weeks
|
Girth will be expressed in cm.
|
For a minimum of 12 weeks
|
|
Possible change,impact on personal clinical parameters: bodyweight
Временное ограничение: For a minimum of 12 weeks
|
Weight will be expressed in kg.
|
For a minimum of 12 weeks
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Главный следователь: Yves Breysem, Dr, Jessa Hospital
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Ожидаемый)
Завершение исследования (Ожидаемый)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Другие идентификационные номера исследования
- 2021/036
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .